精华制药(002349.SZ)：卡左双多巴缓释片获得药品注册证书

Core Viewpoint - The approval of the sustained-release formulation of Carbidopa-Levodopa by the National Medical Products Administration enhances the company's product pipeline in the Parkinson's disease treatment sector, particularly with the introduction of a first generic version in the domestic market [1] Group 1: Product Approval - The company has received two drug registration certificates for Carbidopa-Levodopa sustained-release tablets [1] - The product specifications include Carbidopa 50mg and Levodopa 200mg, making the company the third entity in China to obtain approval for this formulation [1] - The smaller specification of Carbidopa 25mg and Levodopa 100mg is the first generic version in China, with no original research product registered for sale domestically [1] Group 2: Market Impact - The approval enriches the company's offerings in the Parkinson's disease treatment market, providing a significant opportunity in a niche segment [1] - The sustained-release formulation is recognized as the "gold standard" for treating Parkinson's disease according to the "Chinese Parkinson's Disease Treatment Guidelines (2020 Edition)" [1] - The successful approval of the product offers a viable original research alternative for Parkinson's disease patients, particularly benefiting those with mild symptoms through the availability of smaller dosage options [1]